Asset Details
Do you wish to reserve the book?
Low-Dose Naltrexone for the Treatment of Fibromyalgia: Investigation of Dose–Response Relationships
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Low-Dose Naltrexone for the Treatment of Fibromyalgia: Investigation of Dose–Response Relationships
Do you wish to request the book?
Low-Dose Naltrexone for the Treatment of Fibromyalgia: Investigation of Dose–Response Relationships
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Low-Dose Naltrexone for the Treatment of Fibromyalgia: Investigation of Dose–Response Relationships
2020
Overview
Abstract
Objective
This study explores dose–response relationships when treating fibromyalgia with low-dose naltrexone.
Design
A single-blinded clinical trial was carried out using the “up-and-down” method.
Subjects
Subjects included women with a diagnosis of fibromyalgia aged 18–60 years who had been referred to treatment at a public pain clinic at a Danish university hospital.
Methods
The test doses were in the range 0.75–6 mg, and the dosing interval was 0.75 mg. The method was sequential and allowed predicting the dose effective in 50% (ED50) and 95% (ED95) of the subjects when the dose had shifted direction 10 times, and six pairs of “up-and-down” data were available.
Results
A total of 27 subjects were included in the study; two subjects were withdrawn. After inclusion of 25 evaluable subjects, the dose estimates were calculated as 3.88 mg for ED50 and 5.40 mg for ED95. As a secondary outcome, the effects on 10 common fibromyalgia symptoms were evaluated. A high interindividual variation was observed both in the symptom presentation at baseline and in which symptoms were reduced by low-dose naltrexone.
Conclusions
This study is the first to explore dose–response relationships in the treatment of fibromyalgia with low-dose naltrexone. Future placebo-controlled randomized clinical trials are needed, and according to our findings, 4.5 mg, which has previously been used, seems to be a relevant test dose. We recommend that future studies include additional nonpain fibromyalgia symptoms as outcome measures.
Publisher
Oxford University Press
Subject
